Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1997-05-30
1998-10-13
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
424444, 424484, 424488, 424DIG13, A61F 1300, A61K 970
Patent
active
058208747
DESCRIPTION:
BRIEF SUMMARY
This application is a 35 USC 371 of PCT/EP95/2771 filed Jul. 24, 1995.
The present invention is concerned with alginate fibres, and in particular the use thereof as a wound dressing and a method of preparing the same.
Alginate fibres have been known for some time as being useful in the preparation of alginate fabric wound dressings. A number of methods for producing conventional alginate fibres are described in the art. The extrusion of alginate solutions into an aqueous solution containing calcium ions to form calcium alginate filaments is known, for example, from British Patent Specifications Nos. 567641, 568177, 571657 and 624987. The replacement of a proportion of the calcium ions in calcium alginate by sodium ions to produce a more soluble fibre is known from British Patent Specification No. 653341.
Wound dressings including alginate fibres are known to be useful in the treatment of heavily exuding wounds. For example EP 0476756 describes a fabric of alginate fibres suitable for use in the treatment of heavily exuding wounds, the fabric having an absorbency of greater than 25.0 grams of deionised water per gram of fabric. Where a wound is heavily exuding, the use of a high absorbency wound dressing is advantageous in achieving efficient uptake of exudate, together with its associated toxins and other desirable matter, such as proteases and the like.
The presence of proteinaceous material, such as proteases and the like, in a wound environment can be detrimental to the recovery process of the wound. For example, growth factors may be degraded by proteases which could impede the general recovery of the wound. It has therefore been common practice to remove slough, which contains the above described detrimental proteases, from a wound environment to enhance the recovery process. The recovery can be observed by the change of a yellow wound containing a large quantity of slough to a red or pink granulating wound.
Conventionally, proteases are often removed from a wound environment by employing commercially available DEXRANOMER beads or paste which are subsequently removed by irrigation. Removal of the above products can be somewhat traumatic and this problem can be alleviated by the use of a fibrous product, such as alginate wound dressings. However, known alginate dressings take up proteases into the interstitial spaces between the fibres of the fabric and this limits the amount of protease uptake which can be achieved. For example, an alginate wound dressing such as that available under the trade mark KALTOSTAT has been found to have a protease uptake of the order of 4% by weight of the dressing, which can result in the undesirable retention of proteases in the wound environment.
It is therefore desirable to provide a wound dressing, capable of exhibiting improved absorptive properties with respect to proteases present in a wound environment. Alginate fibres have now been discovered suitable for use in the treatment of wounds which alleviate the above problems.
According to the present invention there is provided alginate fibres for use in the absorption of proteinaceous material from a wound environment into the structure of the fibres.
Absorption into the structure of the fibres as referred to above denotes uptake into the fibres themselves as opposed to solely the interstitial spaces therebetween. The ability of alginate fibres to take up proteinaceous material into the structure of the fibre results in considerably improved absorptive properties. The improved absorptive properties resulting from the uptake of proteinaceous material into the structure of the fibres, as opposed to the intersititial spaces between the fibres in an alginate fabric can be seen with reference to the accompanying examples. More specifically, conventional alginate such as that available under the trade mark KALTOSTAT has a protease uptake as described above of the order of 4% by weight, based on the weight of the alginate, whereas alginate fibres capable of absorbing proteases into the structure of the fibres can have a prot
REFERENCES:
patent: 4948575 (1990-08-01), Cloe et al.
patent: 5238685 (1993-08-01), Wren
patent: 5256477 (1993-10-01), Mahoney
patent: 5482932 (1996-01-01), Thompson
patent: 5523093 (1996-06-01), Della Valle et al.
patent: 5540922 (1996-07-01), Fabo
patent: 5618561 (1997-04-01), Della Valle et al.
Howells Anne Elizabeth
Mahoney Peter M. J.
Bristol--Myers Squibb Company
Furman Jr. Theodore R.
Kilcoyne John M.
Page Thurman K.
Shelborne Kathryne E.
LandOfFree
Alginate fibres, method of preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alginate fibres, method of preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alginate fibres, method of preparation and use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-310970